Tag: Aquavit Pharmaceuticals

All

Aquavit Pharmaceuticals, Inc. has submitted to the U.S. FDA an Investigation of New Drug package for a new botulinum toxin, DTX-021.

The acquisition aims to create a new patient acquisition channel by connecting aesthetic practices with corporate skin health and wellness programs.